13 stories mentioning SHA:600276Updated 17d ago
Every FINWIRES story that references SHA:600276, newest first.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) obtained drug registration from China's medical products regulator for its luzinuole sodium tablets.The drug is used for gout with hyperuricemia, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 3% in recent trade.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) said its Guangdong subsidiary received China's regulatory approval to conduct clinical trials for SHR-1819 Injection,The drug is indicated for treating atopic dermatitis in children aged six months to five years, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Chengdu Sdiya Biopharmaceutical received China's regulatory approval to start clinical trials for HRS-1635 tablets.The approval is for the anti-tumor drug's clinical research in B-cell malignancies, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 2% in recent trade.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Suzhou Shengdiya Biopharmaceutical received China's regulatory approval to start clinical trials for SHR-5421.The approval is for the anti-tumor drug's clinical research in multiple myeloma, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 2% in recent trade.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) obtained approval from China's National Medical Products Administration to market a nutritional injection for adult patients in catabolic states, according to a Shanghai bourse filing on Wednesday.The regulatory nod clears the drugmaker to commercialize its omega-3 triglyceride (2%) medium/long chain fat emulsion/amino acid (16)/glucose (30%) injection, which supplies essential parenteral energy and nutrients to patients experiencing moderate to severe catabolism.The company has so far invested 83.9 million yuan into the research and development of the treatment.The pharmaceutical company's shares fell 1% during morning trade on Wednesday.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Suzhou Sundia Biopharmaceuticals obtained the approval of China's drug regulator to begin clinical trials for SHR-3079 injection.The drug is indicated to treat B-cell non-Hodgkin's lymphoma, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% Friday.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Ruishi Biopharmaceuticals obtained the approval of China's drug regulator to begin clinical trials for RSS0393 Latex.The drug is indicated to treat atopic dermatitis, according to a Friday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% Friday.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) subsidiaries obtained clinical trial approval from China's drug regulator for cancer drugs SHR-3821, adebrelimab and rilafusp α.The approved trial is a Phase Ib/II study combining SHR-3821 with other therapies for solid tumors, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 2% in recent trade.
Hong Kong stocks ended slightly lower on Tuesday as fading expectations for progress in U.S.-Iran negotiations and caution ahead of U.S. inflation data weighed on sentiment.The Hang Seng Index shed 0.2%, or 58.93 points, to close at 26,347.91, while the Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,882.37.U.S. President Donald Trump said on Monday that a ceasefire with Iran was "on life support" after Tehran's response to a U.S. proposal highlighted divisions between the two sides.Tehran has called for compensation for war-related damage, an end to the U.S. naval blockade, assurances against further attacks, and the resumption of Iranian oil exports.Markets are also closely watching Trump's visit to China, which begins on Wednesday.In corporate news, Hengrui Pharmaceuticals (HKG:1276, SHA:600276) advanced nearly 5% in Hong Kong after signing a drug development deal with Bristol Myers Squibb worth up to $15.2 billion.
Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) entered into global collaboration and license agreements with Bristol Myers Squibb to develop 13 early-stage programs across oncology, hematology, and immunology, according to a Tuesday Hong Kong bourse filing.The agreements include four oncology and hematology programs from Hengrui, four immunology programs from Bristol Myers Squibb, and five jointly discovered and developed programs.The U.S.-headquartered biopharma company will pay Hengrui up to $950 million, including a $600 million upfront payment, a $175 million first anniversary payment, and a contingent $175 million payment in 2028.The potential total value of the agreements could reach about $15.2 billion, including milestone payments tied to development, regulatory, and commercial targets.Under the deal, Bristol Myers will obtain exclusive worldwide rights to Hengrui-originated programs outside mainland China, Hong Kong, and Macau, while Hengrui will secure exclusive rights to Bristol Myers Squibb-originated programs within those markets.The companies expect the agreements to close in the third quarter, subject to antitrust review and other customary closing conditions.
Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) recorded a 22% rise in attributable profit for the first quarter of 2026 to 2.28 billion yuan from 1.87 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.Earnings per share jumped to 0.34 yuan from 0.30 yuan in the corresponding period of the previous fiscal year.Operating revenue climbed 13% to 8.14 billion yuan from 7.21 billion yuan in the year-ago period.
Jiangsu Hengrui Pharmaceuticals' (SHA:600276) unit, Shandong Shengdi Pharmaceutical, obtained approval from China's National Medical Products Administration for the clinical trials of HRS-7156 tablets, according to a Shanghai bourse filing on Thursday.The drug will be tested as a treatment for heart failure.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) subsidiary Chengdu Shengdi Pharmaceutical obtained China's regulatory approval to begin clinical trials for HRS-5765.The drug is used for treating heart failure, according to a filing with the Shanghai bourse.Shares of the pharmaceutical company closed 3% lower Monday.